{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:04:29Z","timestamp":1781103869661,"version":"3.54.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus and\/or vertigo) with intravenous aminoglycoside and\/or glycopeptide administration in children were performed in PubMed, EMBASE and Cochrane Library databases. Studies with sample sizes of \u226550 children were included. The QUIPS tool and Cochrane criteria were used to assess the quality and risk of bias of included studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-nine aminoglycoside-ototoxicity studies met the selection criteria (including 7 randomized controlled trials). Overall study quality was medium\/low. The frequency of hearing loss within these studies ranged from 0%\u201357%, whereas the frequency of tinnitus and vertigo ranged between 0%\u201353% and 0%\u201379%, respectively. Two studies met the criteria on glycopeptide-induced ototoxicity and reported hearing loss frequencies of 54% and 55%. Hearing loss frequencies were higher in gentamicin-treated children compared to those treated with other aminoglycosides. In available studies aminoglycosides had most often been administered concomitantly with platinum agents, diuretics and other co-medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In children the reported occurrence of aminoglycoside\/glycopeptide ototoxicity highly varies and seems to depend on the diagnosis, aminoglycoside subtype and use of co-administered medication. More research is needed to investigate the prevalence and determinants of aminoglycoside\/glycopeptide ototoxicity. Our results indicate that age-dependent audiological examination may be considered for children frequently treated with aminoglycosides\/glycopeptides especially if combined with other ototoxic medication.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jacamr\/dlab184","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:09:41Z","timestamp":1637237381000},"source":"Crossref","is-referenced-by-count":22,"title":["Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review"],"prefix":"10.1093","volume":"3","author":[{"given":"F A","family":"Diepstraten","sequence":"first","affiliation":[{"name":"Princess M\u00e1xima Center for pediatric oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-5546","authenticated-orcid":false,"given":"A E","family":"Hoetink","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, University Medical Centre Utrecht, UMC Brain Centre, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"van Grotel","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for pediatric oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D R","family":"Huitema","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for pediatric oncology, Utrecht, The Netherlands"},{"name":"Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Stokroos","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, University Medical Centre Utrecht, UMC Brain Centre, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"van den Heuvel-Eibrink","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for pediatric oncology, Utrecht, The Netherlands"},{"name":"Wilhelmina Children\u2019s Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J M","family":"Meijer","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for pediatric oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"2021121406390379400_dlab184-B1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/QCO.0000000000000012","article-title":"Aminoglycosides: how should we use them in the 21st century?","volume":"26","author":"Jackson","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2021121406390379400_dlab184-B2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1517\/14656566.2013.806486","article-title":"Aminoglycoside therapy in infectious diseases","volume":"14","author":"Poulikakos","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2021121406390379400_dlab184-B3","first-page":"6","article-title":"Streptomycin therapy of tuberculosis","volume":"69","author":"Farber","year":"1948","journal-title":"Calif Med"},{"key":"2021121406390379400_dlab184-B4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"2021121406390379400_dlab184-B5","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021121406390379400_dlab184-B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archotol.128.2.150","article-title":"Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis","volume":"128","author":"Stavroulaki","year":"2002","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/cncr.29779","article-title":"Ototoxicity and cancer therapy","volume":"122","author":"Landier","year":"2016","journal-title":"Cancer"},{"key":"2021121406390379400_dlab184-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-319-16435-9_8","volume-title":"Survivors of Childhood and Adolescent Cancer","author":"Landier","year":"2015"},{"key":"2021121406390379400_dlab184-B9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2021121406390379400_dlab184-B10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00128072-200204070-00005","article-title":"Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients","volume":"4","author":"Kraus","year":"2002","journal-title":"Paediatr Drugs"},{"key":"2021121406390379400_dlab184-B11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fncel.2017.00308","article-title":"Aminoglycoside-induced cochleotoxicity: a review","volume":"11","author":"Jiang","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"2021121406390379400_dlab184-B12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/AUD.0000000000000458","article-title":"Systemic aminoglycosides-induced vestibulotoxicity in humans","volume":"38","author":"Van Hecke","year":"2017","journal-title":"Ear Hear"},{"key":"2021121406390379400_dlab184-B13","first-page":"101","article-title":"Aminoglycoside vestibulotoxicity","volume":"82","author":"Rutka","year":"2019","journal-title":"Adv Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1074\/jbc.M113.533588","article-title":"Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases","volume":"289","author":"Shulman","year":"2014","journal-title":"J Biol Chem"},{"key":"2021121406390379400_dlab184-B15","doi-asserted-by":"crossref","first-page":"937861","DOI":"10.1155\/2011\/937861","article-title":"Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection","volume":"2011","author":"Huth","year":"2011","journal-title":"Int J Otolaryngol"},{"key":"2021121406390379400_dlab184-B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00106-019-0662-2","article-title":"Why study inner ear hair cell mitochondria?","volume":"67","author":"Lesus","year":"2019","journal-title":"HNO"},{"key":"2021121406390379400_dlab184-B17","doi-asserted-by":"crossref","first-page":"e0120612","DOI":"10.1371\/journal.pone.0120612","article-title":"Uptake of fluorescent gentamicin by peripheral vestibular cells after systemic administration","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"2021121406390379400_dlab184-B18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10162-009-0160-4","article-title":"Trafficking of systemic fluorescent gentamicin into the cochlea and hair cells","volume":"10","author":"Wang","year":"2009","journal-title":"J Assoc Res Otolaryngol"},{"key":"2021121406390379400_dlab184-B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.heares.2011.05.008","article-title":"New developments in aminoglycoside therapy and ototoxicity","volume":"281","author":"Xie","year":"2011","journal-title":"Hear Res"},{"key":"2021121406390379400_dlab184-B20","first-page":"376","article-title":"Vancomycin ototoxicity and nephrotoxicity. A review","volume":"3","author":"Bailie","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"2021121406390379400_dlab184-B21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","author":"Lestner","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2021121406390379400_dlab184-B22","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021121406390379400_dlab184-B23","first-page":"S18","article-title":"Neonatal therapeutics: considerations for dosing","volume":"36 Suppl 2","author":"Zimmerman","year":"2019","journal-title":"Am J Perinatol"},{"key":"2021121406390379400_dlab184-B24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2021121406390379400_dlab184-B25","author":"Cochrane"},{"key":"2021121406390379400_dlab184-B26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2021121406390379400_dlab184-B27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ciresp.2013.08.002","article-title":"GRADE system: classification of quality of evidence and strength of recommendation","volume":"92","author":"Aguayo-Albasini","year":"2014","journal-title":"Cir Esp"},{"key":"2021121406390379400_dlab184-B28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jac\/35.2.327","article-title":"Gentamicin once-daily versus thrice-daily in children","volume":"35","author":"Elhanan","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"2021121406390379400_dlab184-B29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200103000-00004","article-title":"Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections","volume":"20","author":"Carapetis","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2021121406390379400_dlab184-B30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1651-2227.2003.tb00548.x","article-title":"Treatment of urinary tract infection with gentamicin once or three times daily","volume":"92","author":"Chong","year":"2003","journal-title":"Acta Paediatr"},{"key":"2021121406390379400_dlab184-B31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121406390379400_dlab184-B32","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/j.ijid.2011.04.012","article-title":"A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica","volume":"15","author":"P\u00e9rez","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2021121406390379400_dlab184-B33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2013the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"2021121406390379400_dlab184-B34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006454-198401000-00010","article-title":"Antimicrobial therapy of febrile children with malignancies and possible sepsis","volume":"3","author":"Frazier","year":"1984","journal-title":"Pediatr Infect Dis"},{"key":"2021121406390379400_dlab184-B35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jcf.2014.07.009","article-title":"High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis","volume":"14","author":"Al-Malky","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2021121406390379400_dlab184-B36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/INF.0b013e31821e405d","article-title":"Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity","volume":"30","author":"Best","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2021121406390379400_dlab184-B37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1034\/j.1399-3046.2003.02054.x","article-title":"Risk of hearing impairment in pediatric liver transplant recipients: a single center study","volume":"7","author":"Bucuvalas","year":"2003","journal-title":"Pediatr Transplant"},{"key":"2021121406390379400_dlab184-B38","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1542\/peds.2005-2282","article-title":"Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis","volume":"117","author":"Buckingham","year":"2006","journal-title":"Pediatrics"},{"key":"2021121406390379400_dlab184-B39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0165-5876(81)90002-1","article-title":"Vestibular ototoxicity in children: a retrospective study of 52 cases","volume":"3","author":"Camarda","year":"1981","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.otohns.2009.03.020","article-title":"Sensorineural hearing loss in patients with cystic fibrosis","volume":"141","author":"Cheng","year":"2009","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021121406390379400_dlab184-B42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archotol.124.5.529","article-title":"Sensorineural hearing loss in children after liver transplantation","volume":"124","author":"Deutsch","year":"1998","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B43","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ppul.23763","article-title":"Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides","volume":"52","author":"Handelsman","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2021121406390379400_dlab184-B44","first-page":"192","article-title":"A prospective study of long-term use of amikacin in a paediatrics department. Indications, administration, side-effects, bacterial isolates and resistance","volume":"78","author":"Hesseling","year":"1990","journal-title":"S Afr Med J"},{"key":"2021121406390379400_dlab184-B45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jac\/27.suppl_C.105","article-title":"Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe Gram-negative infections","volume":"27","author":"Kafetzis","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2021121406390379400_dlab184-B46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/INF.0000000000001532","article-title":"Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis","volume":"36","author":"Li","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2021121406390379400_dlab184-B47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF00863438","article-title":"Sensorineural hearing loss in patients reaching chronic renal failure in childhood","volume":"10","author":"Mancini","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"2021121406390379400_dlab184-B48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijporl.2010.01.021","article-title":"Hearing loss in cystic fibrosis","volume":"74","author":"Martins","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijporl.2016.09.001","article-title":"Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients","volume":"90","author":"Olgun","year":"2016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B50","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0165-5876(03)00135-6","article-title":"The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Cl\u00ednicas de Porto Alegre","volume":"67","author":"Piltcher","year":"2003","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/00206097509071734","article-title":"Ototoxicity with children caused by streptomycin","volume":"14","author":"Prazic","year":"1975","journal-title":"Audiology"},{"key":"2021121406390379400_dlab184-B52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/adc.80.2.125","article-title":"Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia","volume":"80","author":"Tomlinson","year":"1999","journal-title":"Arch Dis Child"},{"key":"2021121406390379400_dlab184-B53","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ijporl.2007.08.005","article-title":"Vestibular system in infants after systemic aminoglycoside therapy","volume":"71","author":"Zagolski","year":"2007","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B54","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1044\/2020_AJA-20-00059","article-title":"Functional impacts of aminoglycoside treatment on speech perception and extended high-frequency hearing loss in a pediatric cystic fibrosis cohort","volume":"30","author":"Blankenship","year":"2021","journal-title":"Am J Audiol"},{"key":"2021121406390379400_dlab184-B55","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijporl.2010.02.010","article-title":"Sensorineural deafness in Tanzanian children-is ototoxicity a significant cause? A pilot study","volume":"74","author":"Freeland","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B56","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/AUD.0000000000000682","article-title":"Medical referral patterns and etiologies for children with mild-to-severe hearing loss","volume":"40","author":"Judge","year":"2019","journal-title":"Ear Hear"},{"key":"2021121406390379400_dlab184-B57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0033-3506(96)80092-8","article-title":"Hearing impairment among young Chinese in a rural area","volume":"110","author":"Morioka","year":"1996","journal-title":"Public Health"},{"key":"2021121406390379400_dlab184-B58","doi-asserted-by":"crossref","first-page":"110401","DOI":"10.1016\/j.ijporl.2020.110401","article-title":"Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer","volume":"138","author":"Rajput","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B59","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM198005153022002","article-title":"Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin","volume":"302","author":"Smith","year":"1980","journal-title":"N Engl J Med"},{"key":"2021121406390379400_dlab184-B60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archotol.1990.01870040028008","article-title":"The incidence of aminoglycoside antibiotic-induced hearing loss","volume":"116","author":"Brummett","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B61","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.anorl.2017.12.008","article-title":"International consensus (ICON) on audiological assessment of hearing loss in children","volume":"135 Suppl 1","author":"Farinetti","year":"2018","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"2021121406390379400_dlab184-B62","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamaoncol.2021.2697","article-title":"Recommendations for age-appropriate testing, timing, and frequency of audiologic monitoring during childhood cancer treatment: an International Society of Paediatric Oncology supportive care consensus report","volume":"7","author":"Meijer","year":"2021","journal-title":"JAMA Oncol"},{"key":"2021121406390379400_dlab184-B63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0039-1684041","article-title":"A review of cisplatin-associated ototoxicity","volume":"40","author":"Paken","year":"2019","journal-title":"Semin Hear"},{"key":"2021121406390379400_dlab184-B64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021121406390379400_dlab184-B65","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/MPH.0000000000001282","article-title":"Cisplatin-induced ototoxicity in children with solid tumor","volume":"41","author":"Wei","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021121406390379400_dlab184-B66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005537-199604000-00003","article-title":"Ototoxicity resulting from combined administration of cisplatin and gentamicin","volume":"106","author":"Riggs","year":"1996","journal-title":"Laryngoscope"},{"key":"2021121406390379400_dlab184-B67","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1288\/00005537-199107000-00004","article-title":"Toxic effects of cisplatin alone and in combination with gentamicin in stria vascularis of guinea pigs","volume":"101","author":"Kohn","year":"1991","journal-title":"Laryngoscope"},{"key":"2021121406390379400_dlab184-B68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archotol.1990.01870010065019","article-title":"Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs","volume":"116","author":"Brummett","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B69","doi-asserted-by":"crossref","first-page":"C1187","DOI":"10.1152\/ajpcell.00024.2007","article-title":"Functional significance of channels and transporters expressed in the inner ear and kidney","volume":"293","author":"Lang","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2021121406390379400_dlab184-B70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/014107689108401006","article-title":"Hearing loss in chronic renal failure-hearing threshold changes following haemodialysis","volume":"84","author":"Gatland","year":"1991","journal-title":"J R Soc Med"},{"key":"2021121406390379400_dlab184-B71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12882-020-01810-z","article-title":"The association between reduced kidney function and hearing loss: a cross-sectional study","volume":"21","author":"Liu","year":"2020","journal-title":"BMC Nephrol"},{"key":"2021121406390379400_dlab184-B72","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00467-016-3533-z","article-title":"Aminoglycoside-induced nephrotoxicity in children","volume":"32","author":"McWilliam","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2021121406390379400_dlab184-B73","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/INF.0000000000002391","article-title":"Vancomycin-associated nephrotoxicity and risk factors in critically ill children without preexisting renal injury","volume":"38","author":"Feiten","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2021121406390379400_dlab184-B74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/archdischild-2015-309069","article-title":"What do I need to know about aminoglycoside antibiotics?","volume":"102","author":"Germovsek","year":"2017","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2021121406390379400_dlab184-B75","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1128\/AAC.00577-16","article-title":"Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants","volume":"60","author":"Germovsek","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121406390379400_dlab184-B76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3766\/jaaa.14104","article-title":"Risk factors for hearing loss in patients with cystic fibrosis","volume":"27","author":"Tarshish","year":"2016","journal-title":"J Am Acad Audiol"},{"key":"2021121406390379400_dlab184-B77","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/pbc.24631","article-title":"Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides","volume":"60","author":"Chen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2021121406390379400_dlab184-B78","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1542\/peds.112.5.1049","article-title":"Hearing loss at school age in survivors of bacterial meningitis: assessment, incidence, and prediction","volume":"112","author":"Koomen","year":"2003","journal-title":"Pediatrics"},{"key":"2021121406390379400_dlab184-B79","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archotol.132.9.941","article-title":"Clinical predictors for hearing loss in children with bacterial meningitis","volume":"132","author":"Kutz","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1750-3639.2003.tb00012.x","article-title":"Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis","volume":"13","author":"Klein","year":"2003","journal-title":"Brain Pathol"},{"key":"2021121406390379400_dlab184-B81","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0003489415573960","article-title":"Labyrinthitis ossificans: on the mechanism of perilabyrinthine bone remodeling","volume":"124","author":"Bloch","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021121406390379400_dlab184-B82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00457456","article-title":"An experimental study of vancomycin-induced cochlear damage","volume":"246","author":"Tange","year":"1989","journal-title":"Arch Otorhinolaryngol"},{"key":"2021121406390379400_dlab184-B83","first-page":"2291","article-title":"Vancomycin-induced ototoxicity in very-low-birthweight infants","volume":"75","author":"Marissen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021121406390379400_dlab184-B84","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S1474-4422(13)70160-1","article-title":"Tinnitus: causes and clinical management","volume":"12","author":"Langguth","year":"2013","journal-title":"Lancet Neurol"},{"key":"2021121406390379400_dlab184-B85","doi-asserted-by":"crossref","first-page":"561185","DOI":"10.3389\/fnins.2020.561185","article-title":"A novel mouse model of aminoglycoside-induced hyperacusis and tinnitus","volume":"14","author":"Longenecker","year":"2020","journal-title":"Front Neurosci"},{"key":"2021121406390379400_dlab184-B86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3988\/jcn.2009.5.1.11","article-title":"Tinnitus: characteristics, causes, mechanisms, and treatments","volume":"5","author":"Han","year":"2009","journal-title":"J Clin Neurol"},{"key":"2021121406390379400_dlab184-B87","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00431-006-0320-z","article-title":"Characteristics of tinnitus in childhood","volume":"166","author":"Savastano","year":"2007","journal-title":"Eur J Pediatr"},{"key":"2021121406390379400_dlab184-B88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0194599819887375","article-title":"Prevalence of pediatric dizziness and imbalance in the United States","volume":"162","author":"Brodsky","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021121406390379400_dlab184-B89","first-page":"38","article-title":"Ototoxic side effects of the streptomycins, in particular dihydrostreptomycin","volume":"53","author":"Falbe-Hansen","year":"1972","journal-title":"Scand J Respir Dis"},{"key":"2021121406390379400_dlab184-B90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3349\/ymj.2003.44.3.517","article-title":"Comparative vestibulotoxicity of different aminoglycosides in the guinea pigs","volume":"44","author":"Selimo\u011flu","year":"2003","journal-title":"Yonsei Med J"},{"key":"2021121406390379400_dlab184-B91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/WCO.0000000000000157","article-title":"Vertigo and dizziness in children","volume":"28","author":"Jahn","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"2021121406390379400_dlab184-B92","doi-asserted-by":"crossref","first-page":"e0210646","DOI":"10.1371\/journal.pone.0210646","article-title":"A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy","volume":"14","author":"Clemens","year":"2019","journal-title":"PLoS One"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab184\/41742726\/dlab184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab184\/41742726\/dlab184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T19:33:22Z","timestamp":1673811202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab184\/6460598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab184","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,30]]},"article-number":"dlab184"}}